Ponesimod vs Siponimod (Mayzent)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
NCT02425644 · Phase 3 · completed
This large, randomized, double-blind trial compared ponesimod head-to-head against an approved active comparator (teriflunomide) using relapse rate, a core clinical measure of multiple sclerosis activity, and ponesimod met its primary endpoint with a statistically significant roughly 30% relative reduction in relapses.
Reported efficacy
Annualized Confirmed Relapse Rate (From randomization to end of study (Week 108)): Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. (met)
Result source: NCT02425644
Siponimod (Mayzent)
Marketed by Novartis
NCT03623243 · Phase 3 · completed
The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.
Reported efficacy
Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) (Baseline, every 3 month up to the maximum of approximately 3 years): EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). (met)
Result source: NCT01665144
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ponesimod | Siponimod (Mayzent) |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3vs TeriflunomideNCT02425644 | —Trial running · NCT04926818 |
| Free of 3-month confirmed disability progression (%) | —Not reported | —Trial running · NCT04926818 |
| New or enlarging T2 lesions | —Not reported | —Trial running · NCT04926818 |
Annualised relapse rate
- Ponesimod
- 0.2 vs 0.3vs TeriflunomideNCT02425644
- Siponimod (Mayzent)
- —Trial running · NCT04926818
Free of 3-month confirmed disability progression (%)
- Ponesimod
- —Not reported
- Siponimod (Mayzent)
- —Trial running · NCT04926818
New or enlarging T2 lesions
- Ponesimod
- —Not reported
- Siponimod (Mayzent)
- —Trial running · NCT04926818
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ponesimod: 4 of 4 rows · Siponimod (Mayzent): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ponesimod | Siponimod (Mayzent) |
|---|---|---|
| Dropout rate | 13.6%20 mga NCT02425644 · Phase 3 show 4 more results19.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 33.9%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 35%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 38.3%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence | 21.1%a NCT03623243 · Phase 3 |
| Discontinued due to AEs | 2.3%20 mga NCT02425644 · Phase 3 show 4 more results1.6%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 0.8%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 3.4%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 1.7%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence | 8.1%a NCT03623243 · Phase 3 |
| Serious AEs | 8.7%20 mga NCT02425644 · Phase 3 show 4 more results12.8%20 mg NCT03232073 · Phase 3 · registry result, not featured evidence 24.1%20 mg NCT01093326 · Phase 2 · registry result, not featured evidence 16.6%40 mg NCT01093326 · Phase 2 · registry result, not featured evidence 23%10 mg NCT01093326 · Phase 2 · registry result, not featured evidence | 4.9%a NCT03623243 · Phase 3 |
| Most frequent reported AEs | 20 mga alanine aminotransferase increased 19.5% nasopharyngitis 19.3% headache 11.3% NCT02425644 · Phase 3 show 4 more results20 mg covid-19 26.2% nasopharyngitis 18.7% alanine aminotransferase increased 16.6% NCT03232073 · Phase 3 · registry result, not featured evidence 20 mg nasopharyngitis 31.7% headache 21.4% upper respiratory tract infection 19.3% NCT01093326 · Phase 2 · registry result, not featured evidence 40 mg nasopharyngitis 29.8% headache 27.2% upper respiratory tract infection 25.8% NCT01093326 · Phase 2 · registry result, not featured evidence 10 mg nasopharyngitis 33.1% headache 27.3% upper respiratory tract infection 19.4% NCT01093326 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ponesimod
show 1 more result
show 1 more result
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ponesimod's landscape · Siponimod (Mayzent)'s landscape